UK markets open in 2 hours 55 minutes
  • NIKKEI 225

    28,677.13
    -841.21 (-2.85%)
     
  • HANG SENG

    27,989.37
    -606.29 (-2.12%)
     
  • CRUDE OIL

    64.45
    -0.47 (-0.72%)
     
  • GOLD FUTURES

    1,835.20
    -2.40 (-0.13%)
     
  • DOW

    34,742.82
    -34.94 (-0.10%)
     
  • BTC-GBP

    39,136.00
    -3,159.64 (-7.47%)
     
  • CMC Crypto 200

    1,452.64
    -108.66 (-6.96%)
     
  • ^IXIC

    13,401.86
    -350.38 (-2.55%)
     
  • ^FTAS

    4,060.80
    -5.38 (-0.13%)
     

Interventional Robotics Startup Moray Medical Boosts Seed Financing to $5.7 Million

·1-min read

Moray Medical announced today that it has closed a total of $5.7 million in seed funding, an increase of $2.4 million compared to the initial raise reported on 01/27/2021. Investors included 415 CAPITAL (lead), Heal Capital, as well as a number of prominent medtech entrepreneurs, such as Fred St. Goar, MD, inventor of the MitralClip™ transcatheter mitral valve repair (TMVR) system.

The company will use the funding to continue development of its CoralTM system, an innovative interventional robotics platform powered by microfluidics and an augmented reality (AR) digital user interface. While the Coral platform promises to dramatically simplify a wide range of minimally invasive cardiovascular interventions, Moray Medical is initially focused on the rapidly growing transcatheter mitral valve repair (TMVR) market.

"There is no argument that transcatheter edge-to-edge repair (TEER), or clip therapy, is steadily evolving into the new clinical standard for heart valve repair. However, the intricacy and learning curve required by currently marketed devices means that the overwhelming majority of sick patients are not receiving treatment," said Mark Barrish, CEO and Co-Founder of Moray Medical.

"Our Coral platform is designed to empower interventionalists at all skill levels not only to carry out these procedures but also to do so in a cost-efficient manner, with the goal of making certain that millions of additional sick patients who cannot be currently treated will get the life-saving intervention they need," added Barrish.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210412005591/en/

Contacts

Ronald Trahan, APR, Ronald Trahan Associates, ron@ronaldtrahan.com, 508-816-6730